229 results on '"Ingre, Caroline"'
Search Results
2. Repeated cognitive assessments show stable function over time in patients with ALS
3. Increased incidence of motor neuron disease in Sweden: a population-based study during 2002–2021
4. Biomarkers in amyotrophic lateral sclerosis: current status and future prospects
5. ECAS correlation with metabolic alterations on FDG-PET imaging in ALS
6. The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review
7. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression
8. Medication use and risk of amyotrophic lateral sclerosis—a systematic review
9. Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial
10. Motor band sign is specific for amyotrophic lateral sclerosis and corresponds to motor symptoms.
11. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
12. Altered perivascular fibroblast activity precedes ALS disease onset
13. Hospital-treated infections in early- and mid-life and risk of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden
14. Neurodegenerative biomarkers outperform neuroinflammatory biomarkers in amyotrophic lateral sclerosis.
15. Neurodegenerative biomarkers outperform neuroinflammatory biomarkers in amyotrophic lateral sclerosis
16. A randomized, double‐blind, placebo‐controlled, phase 2 study to assess safety, tolerability and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
17. FDG-PET shows weak correlation between focal motor weakness and brain metabolic alterations in ALS
18. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay.
19. Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS).
20. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success
21. PRECISION ALS—an integrated pan European patient data platform for ALS
22. Diagnostic delay in amyotrophic lateral sclerosis
23. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
24. No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
25. PERIVASCULAR FIBROBLASTS ACTIVITY PRECEDES THE ONSET OF ALS NEURODEGENERATION WITH HIGH PLASMA SPP1 ASSOCIATED WITH SHORT PATIENT SURVIVAL
26. UNC13Ain amyotrophic lateral sclerosis: from genetic association to therapeutic target
27. UNC13A in amyotrophic lateral sclerosis: from genetic association to therapeutic target.
28. Publisher Correction: Altered perivascular fibroblast activity precedes ALS disease onset
29. Amyotrophic lateral sclerosis among cross-country skiers in Sweden
30. Dying from ALS in Sweden: clinical status, setting, and symptoms.
31. Lithium carbonate in Amyotrophic Lateral Sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A; protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial.
32. Structural magnetic resonance imaging findings and histopathological correlations in motor neuron diseases—A systematic review and meta-analysis
33. Dying from ALS in Sweden: clinical status, setting, and symptoms
34. Dying from ALS in Sweden: clinical status, setting, and symptoms
35. The path to diagnosis in ALS: delay, referrals, alternate diagnoses, and clinical progression.
36. The path to diagnosis in ALS: delay, referrals, alternate diagnoses, and clinical progression
37. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
38. Clinical trials in pediatric ALS: a TRICALS feasibility study
39. Author response: Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
40. Additional file 1 of Medication use and risk of amyotrophic lateral sclerosis—a systematic review
41. Structural magnetic resonance imaging findings and histopathological correlations in motor neuron diseases—A systematic review and meta-analysis
42. A yeast functional screen predicts new candidate ALS disease genes
43. Structural Magnetic Resonance Imaging Findings and Histopathological Correlations in Human and Animal Motor Neuron Diseases – A Systematic Review and Meta-Analysis
44. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis: a longitudinal cohort study
45. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
46. Mortality among family members of patients with amyotrophic lateral sclerosis – a Swedish register-based study
47. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study
48. Cardiac troponin T is elevated and increases longitudinally in ALS patients
49. Multivariate Analysis of Blood Biomarkers in Amyotrophic Lateral Sclerosis
50. Mortality among family members of patients with amyotrophic lateral sclerosis – a Swedish register-based study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.